GlobeNewswire

Sigma Designs Names New Z-Wave Certification Test House in China

Dela

 

The Institute of Digital Guangdong to Provide Independent Technical Certification

FREMONT, Calif., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Sigma Designs® (NASDAQ:SIGM), a leading provider of intelligent system-on-chip (SoC) solutions for Connected Smart TV platforms and Smart home IoT, today announces the Institute of Digital Guangdong (IDG) will serve as a new Z-Wave Certification Test House in China, to expand certification testing capabilities in Asia.

Z-Wave Certification ensures interoperability between Z-Wave products. All Z-Wave products must be certified before launch on the commercial market and once certified, will display Z-Wave interoperability logo badges. There are two components to Z-Wave certification. Technical certification is managed through Sigma Designs utilizing independent, third-party test houses and Market Certification is managed through the Z-Wave Alliance.

"We know the smart home market has great potential in China. We have chosen to work with IDG to better serve the growing Z-Wave market and give our customers who are creating smart home experiences in China a quicker path to certification and thus the commercial market," said Raoul Wijgergangs, VP of Sigma Designs' Z-Wave Business Unit.

Sigma Designs currently has approximately 340 companies registered on the Z-Wave Plus Certification Portal, representing 35 different countries. At least 40 of those companies are from mainland China and five from Hong Kong.

"As a new certification facility, we are excited to promote the use of the Z-Wave technology in the market and are committed to facilitating the industrial deployment of the Z-Wave technology," said Dr. Li Ying, Executive Vice President of IDG.

IDG will serve as the independent, third-party technical certification test house in China beginning Oct. 9. This expands the global presence of authorized test partners and gives developers the option of using BuLogics in Philadelphia Pennsylvania, Pepper-One in Zwickau Germany and now, IDG in Guangzhou China for technical certification.

About Sigma Designs
Sigma Designs, Inc. (NASDAQ:SIGM) is a world leader in enabling smart home convergence. The company designs and builds the essential semiconductor technologies that serve as the foundation for the world's leading Connected Smart TV platforms, and Internet of Things (IoT) for smart home devices. For more information about Sigma Designs, please visit www.sigmadesigns.com.

About Z-Wave
Z-Wave technology is an open internationally recognized ITU standard (G.9959). It is the leading wireless home control technology in the market today, with over 2100 certified interoperable products worldwide. Represented by the Z-Wave Alliance, and supported by more than 600 companies around the world, the standard is a key enabler of smart living solutions for home safety and security, energy, hospitality, office and light commercial applications.

Z-Wave® is a registered trademark of Sigma Designs and its subsidiaries in the United States and other countries.

About IDG
Institute of Digital Guangdong (IDG), the South China Branch of Institute of Digital China in Peking University (IDC/PKU), was founded in April 2009 as a provincial public service institution to provide experience and support for the vision of digital technology, industry and economy in China.

Under the guidance of IDC/PKU and the Economic and Information Commission of Guangdong Province, IDG is dedicated to Digital Guangdong and Digital China development by bridging government bodies, industrial sectors, academic communities and research institutions, with a focus on consultancy and research, application promotion, industrial development, talent training, and international cooperation.

Currently, IDG also serves as the Secretariat of the Guangdong RFID Standards Commission, responsible for the daily operation of the institution.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements about consumer adoption, and the anticipated features and benefits of Sigma's products and solutions with respect to Z-Wave and various Z-Wave offerings. Actual results may vary materially due to a number of factors including, but not limited to, consumer and customer acceptance of Z-Wave and Z-Wave new test house provider, Sigma's ability to deploy and achieve market acceptance for Sigma's products in its target markets, including the IoT market, the relative success of the new test house provider, the overall ability Z-Wave development kit, chipsets and modules to compete with other technologies or products in these markets as well as other risks that are detailed from time to time in Sigma's SEC reports, including its report on Form 10-K. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Sigma undertakes no obligation to publicly release or otherwise disclose any revision to these forward-looking statements that may be made as a result of events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Press Contacts:
Mary Miller                                                                  Alexandra Crabb        
Sigma Designs                                                           Caster Communications
+1-510-897-1069                                                        +1-401-792-7080
Mary_Miller@sigmadesigns.com                               alex@castercomm.com

 
 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sigma Designs, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum